Aether's general partners combine scientific asset development, clinical diligence, healthcare M&A, investment management, and capital formation to evaluate opportunities across therapeutic innovation and the businesses that support its development and delivery.
Elizabeth Parrish leads Aether's Science & Asset Strategy, focusing on biotechnology opportunity sourcing, scientific differentiation, and asset-development priorities. As BioViva's founder and CEO and a named gene-therapy patent inventor, she brings experience building investigational programs for age-related disease. Her role connects the fund's innovation strategy with the scientific expertise, development capabilities, and partnerships needed to evaluate and advance promising therapeutic platforms.
Tucson Dunn leads Aether's M&A, Integration & Operations, bringing international healthcare transaction and operating experience to the fund's acquisition strategy. His background includes healthcare M&A at Fosun, hospital-division leadership at Medicover, and multi-site operational transformation. He focuses on a target's operating quality, integration requirements, and improvement opportunities, connecting acquisition assessment with the management and execution needed to develop the business after investment.
Eugene Durenard leads Aether's Fund Structure & Investment Strategy, drawing on institutional asset management, healthcare investing, and family-office advisory experience. A co-founder of Orion Investment Management with chief investment officer experience at Healthcare Impact Holdings, he focuses on fund architecture, capital allocation, and portfolio construction. His role connects the merits of individual opportunities with their financing requirements, development timelines, risks, and fit within Aether's overall strategy.
Jordan Dawson leads Aether's Clinical Strategy & Portfolio Development, combining healthcare opportunity sourcing with clinical and translational diligence, evidence strategy, and portfolio oversight. Her experience in pharmaceutical medical affairs, healthcare acquisition diligence, and clinical leadership informs the assessment of scientific credibility, therapeutic differentiation, and adoption potential. She also evaluates the clinical and operating capabilities that healthcare businesses can contribute to Aether's broader innovation and commercialization strategy.
Daniel Passarelli leads Aether's Capital Formation & Investor Relations, focusing on investor development, capital relationships, and financing coordination. His experience at Dominus Capital Group includes acquisition origination, capital sourcing, and equity-partnership strategies. Combined with healthcare business ownership, that background informs his work connecting Aether's investment thesis and capital requirements with prospective investors whose objectives and investment horizons fit the fund's strategy.
Aether applies AI across the fund's plan and portfolio operations — guided by a dedicated implementation advisor.
Founder of My Horizon, where the team develops AI-enabled software and business automation. A former SpaceX team member, his work spans AI agent systems (Synthios), collaboration on Tool Savants' Pocket Marketer, acquisition research, and decision-support tools — connecting business information, automating repetitive workflows, and keeping key decisions under human review.
Daniel advises Aether on applying AI across the fund's plan and portfolio operations, translating emerging capabilities into practical tools for owners, operators and their teams.
Important information. Confidential discussion material for accredited investors only; not an offer or solicitation. Team and adviser roles are described for context and are subject to definitive documentation. Nothing here is a performance representation, promise or guarantee.